Feladilimab
Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma.
Overview
Feladilimab is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by GlaxoSmithKline, in multiple myeloma. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.
1.Feladilimab binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Feladilimab" OR ABSTRACT:"Feladilimab" OR TITLE:"GSK3359609" OR ABSTRACT:"GSK3359609") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Feladilimab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAZD0120
Shares Multiple myeloma and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares the tags pipeline, registry-only.
- TreatmentAlisertib
Shares the tags pipeline, registry-only.
- TreatmentAMO959
Shares the tags pipeline, registry-only.
- TreatmentAMT-116
Shares the tags pipeline, registry-only.
- TreatmentARD103
Shares the tags pipeline, registry-only.
- TreatmentAU-007
Shares the tags pipeline, registry-only.
- TreatmentAVZO-023
Shares the tags pipeline, registry-only.